Press coverage about Solid Biosciences (NASDAQ:SLDB) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Solid Biosciences earned a news impact score of -0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.0248387446565 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
Shares of SLDB traded down $0.04 during trading hours on Friday, hitting $9.54. 143,584 shares of the company were exchanged, compared to its average volume of 682,111. The firm has a market cap of $339.87 and a P/E ratio of -3.31. Solid Biosciences has a fifty-two week low of $6.83 and a fifty-two week high of $33.74.
A number of research analysts have commented on SLDB shares. Nomura decreased their price objective on Solid Biosciences from $52.00 to $37.00 and set a “buy” rating on the stock in a report on Monday, March 19th. Chardan Capital started coverage on Solid Biosciences in a report on Wednesday, February 21st. They issued a “buy” rating and a $40.00 price objective on the stock. Instinet started coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Leerink Swann decreased their price objective on Solid Biosciences from $36.00 to $14.00 and set a “hold” rating on the stock in a report on Monday, April 2nd. Finally, JPMorgan Chase began coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a “neutral” rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $33.67.
In related news, Director Life Sciences Maste Perceptive bought 1,020,000 shares of Solid Biosciences stock in a transaction dated Tuesday, January 30th. The shares were bought at an average cost of $16.22 per share, with a total value of $16,544,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
WARNING: “Solid Biosciences (NASDAQ:SLDB) Given Coverage Optimism Rating of -0.01” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/solid-biosciences-sldb-earns-news-sentiment-score-of-0-01.html.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.